2545 Golden Bear Drive
38 articles about Gradalis Inc.
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control.
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
Gradalis, Inc. announced a peer-reviewed publication in Cancers, highlighting the newly discovered critical clinical role of clonal neoantigens in the durable efficacy of immunotherapies in oncology and the potential to use clonal neoantigens as a new biomarker to better identify patients who will best respond to certain immunotherapies.
Gradalis, Inc. announced that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas.
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer on Wednesday, October 25, 2023 at 11:00am ET.
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile.
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference, being held in New York, NY from September 26-28, 2023.
Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
Gradalis Inc. announced the peer-reviewed publication in Advanced NanoBioMed, highlighting the therapeutic applications of a new extracellular matrix platform developed for tumor cell expansion in collaboration with the University of Michigan Biointerfaces Institute.
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.
Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma
Gradalis, Inc. today announced that data from a pilot study evaluating Vigil in combination therapy for the management of recurrent Ewing’s Sarcoma was published online in Clinical Cancer Research.
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will provide a corporate update at the BIO CEO & Investor Conference being held both virtually and in New York, NY on February 6-9, 2023.
Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.
Gradalis today announced it has received clearance by the U.S. Food and Drug Administration (FDA) to proceed with the registrational Phase 3 VITAL-V study for Vigil® (gemogenovatucel-T) in patients with advanced ovarian cancer.
Gradalis, a privately-held, late-stage stage biotechnology company developing immunotherapies for ovarian and other cancers, announced the appointment of Eric Hall, CFA, as Chief Financial Officer, effective January 1, 2023.
Gradalis, Inc. announced that Steven Engle, Chief Executive Officer, will provide a corporate update at the 2022 Cell & Gene Meeting on the Mesa being held both virtually and in Carlsbad, California on October 11 – 13, 2022.
Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors
Gradalis, Inc. announced a peer-reviewed publication in Clinical Medicine Insights: Oncology demonstrating positive results from a pilot study investigating Vigil® in combination with a PD-L1 checkpoint inhibitor, durvalumab, in patients with advanced triple negative breast cancer or recurrent/refractory ovarian cancer.
Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®
Gradalis today announced that it will host a key opinion leader (KOL) webinar on the current treatment landscape for ovarian cancer and Vigil ® , the company’s fully personalized, patient-specific cancer immunotherapy, on Monday, October 3, 2022 at 1:00 p.m. ET.
Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®
Gradalis Inc. announced a peer-reviewed publication today in the Nature portfolio journal, Communications Medicine, in which several biomarkers were evaluated for their potential to predict survival following Vigil® (Gemogenovatucel-T) treatment.
Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced that Steven Engle has joined the company as its Chief Executive Officer.
Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type ( BRCA -wt) profile and homologous recombination proficiency (HRP) have been published in Gynecologic Oncology. Patients treated with Vigil experienced improved overall survival (OS) and recurrence free survival (RFS) compared to placebo. No Grade 3 or 4 toxicities were observed in the Vigil-treated group.
CryoPort Supports Gradalis Inc.'s Vigil Platform In Clinical Trials For Autologous Immunotherapies For Multiple Cancers
Gradalis Inc. Announces A Novel Combination Study Of Vigil EATC In Women With Advanced Ovarian Cancer